Ablynx announced the appointment of Daniel Schneider as the General Manager to lead the commercialisation of caplacizumab in North America.
Schneider will be based in a US office, to be located on the East Coast. Caplacizumab is the company's wholly-owned anti-von Willebrand factor (vWF) Nanobody being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
Schneider has 25 years of experience in establishing and leading the commercial operations for a number of companies in the life sciences industry and has been deeply involved in the successful launch of many pharmaceutical products, including those for orphan indications.
Until recently, Schneider was the General Manager of the Specialty Pharmaceuticals Business Unit at BTG International. Previously, he held senior commercial roles at a number of life science companies where he developed the commercial strategy and led the sales efforts across all sectors of the business.
Schneider holds a BSBA from Saint Louis University and an MBA from Washington University in St Louis.
Dr Edwin Moses, CEO of Ablynx, said: "We are very pleased that Dan is joining us. He brings many years of experience in setting up commercial organisations and leading multiple successful product launches in the US. We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab."
Schneider said: "I am delighted to join Ablynx at this very important moment as the company prepares for the potential launch of its first product. I look forward to building and leading the commercial activities in North America and contributing to the growth of the company."
